Live News EQUITY L impact Jul 28, 2026, 11:45 AM UTC

LTRN Lantern Pharma to advance EMA-cleared phase 1B/2 trial of lp-184 (zirdafulven) in biomarker-selected advanced bladder cancer

LTRN Lantern Pharma to advance EMA-cleared phase 1B/2 trial of lp-184 (zirdafulven) in biomarker-selected advanced bladder cancer

SquawkNews Newsroom

LTRN Lantern Pharma to advance EMA-cleared phase 1B/2 trial of lp-184 (zirdafulven) in biomarker-selected advanced bladder cancer